Review
Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
Kyung Hoon Cho, Young Joon Hong
Korean J Intern Med. 2020;35(5):1045-1058. Published online August 28, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the degradation of low-density lipoprotein (LDL) receptors; it has been proved that its inhibition improves cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD). Herein, we review the current..
|